Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study

BACKGROUND: Alectinib, a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), is highly effective in advanced ALK-rearranged non-small-cell lung cancer and represents a standard first-line therapy. New strategies are needed, however, to delay resistance. We conducted a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, J.J., Muzikansky, A., Kennedy, E., Kuberski, H., Stober, L.L., Wanat, A.C., Azzoli, C.G., Lennes, I., Sequist, L.V., Dagogo-Jack, I., Shaw, A.T., Gainor, J.F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666648/
https://www.ncbi.nlm.nih.gov/pubmed/34896762
http://dx.doi.org/10.1016/j.esmoop.2021.100342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666648/
https://www.ncbi.nlm.nih.gov/pubmed/34896762
http://dx.doi.org/10.1016/j.esmoop.2021.100342

Ejemplares similares